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Several different members of the Polyomaviridae, including some human pathogens, encode microRNAs
(miRNAs) that lie antisense with respect to the early gene products, the tumor (T) antigens. These miRNAs
negatively regulate T antigen expression by directing small interfering RNA (siRNA)-like cleavage of the early
transcripts. miRNA mutant viruses of some members of the Polyomaviridae express increased levels of early
proteins during lytic infection. However, the importance of miRNA-mediated negative regulation of the T
antigens remains uncertain. Bandicoot papillomatosis carcinomatosis virus type 1 (BPCV1) is associated with
papillomas and carcinomas in the endangered marsupial the western barred bandicoot (Perameles bougain-
ville). BPCV1 is the founding member of a new group of viruses that remarkably share distinct properties in
common with both the polyomavirus and papillomavirus families. Here, we show that BPCV1 encodes, in the
same orientation as the papillomavirus-like transcripts, a miRNA located within a long noncoding region
(NCR) of the genome. Furthermore, this NCR serves the function of both promoter and template for the
primary transcript that gives rise to the miRNA. Unlike the polyomavirus miRNAs, the BPCV1 miRNA is not
encoded antisense to the T antigen transcripts but rather lies in a separate, proximal region of the genome. We
have mapped the 3 untranslated region (UTR) of the BPCV1 large T antigen early transcript and identified
a functional miRNA target site that is imperfectly complementary to the BPCV1 miRNA. Chimeric reporters
containing the entire BPCV1 T antigen 3 UTR undergo negative regulation when coexpressed with the BPCV1
miRNA. Notably, the degree of negative regulation observed is equivalent to that of an identical reporter that
is engineered to bind to the BPCV1 miRNA with perfect complementarity. We also show that this miRNA and
this novel mode of early gene regulation are conserved with the related BPCV2. Finally, papillomatous lesions
from a western barred bandicoot express readily detectable levels of this miRNA, stressing its likely importance
in vivo. Combined, the alternative mechanisms of negative regulation of T antigen expression between the
BPCVs and the polyomaviruses support the importance of miRNA-mediated autoregulation in the life cycles
of some divergent polyomaviruses and polyomavirus-like viruses.
MicroRNAs (miRNAs) are small, approximately 22-nucle-
otide (nt) regulatory RNA molecules that have been shown to
play an important role in numerous fields, including virology
and immunology (reviewed in references 3, 9, 37, and 43).
Virus-encoded miRNAs that target viral or host transcripts
have been identified (35, 38). In some cases, mutant viruses
defective for miRNA production have been shown to have
altered activities of obvious relevance to virus infection. Some
activities associated with virus-encoded miRNAs include eva-
sion of the innate immune response (36) and control of the
switch from latent to lytic infection (24, 26). Thus, miRNAs
represent a strategy used by several different virus families for
optimizing their infectious life cycle.
miRNA biogenesis has been reviewed in depth (see refer-
ences 12 and 22). In brief, miRNAs are derived from longer
primary transcripts (pri-miRNAs) that contain a hairpin struc-
ture called a precursor miRNA (pre-miRNA). The nuclear
endonuclease Drosha “liberates” the hairpin pre-miRNA (23,
47), which is then exported to the cytoplasm and further pro-
cessed into the 22-nt form by the Dicer endonuclease (8, 20).
This final miRNA product is stabilized within the cytoplasmic
multiprotein RNA induced silencing complex (RISC) (18).
RISC-bound miRNAs associate with mRNA target transcripts,
typically by binding to the 3 untranslated (UTR) region with
imperfect complementarity (3). This results in inhibition of
protein production and the indirect nucleolytic turnover of the
targeted transcripts. However, though it is rare in animals,
miRNAs encoded by plants and some viruses can also bind to
target mRNAs with perfect complementarity and direct a spe-
cific, RISC-mediated endonucleolytic cleavage of that targeted
transcript. Typically, this cleavage occurs in the coding portion
of the transcript. In this mode, miRNAs act via a mechanism
that is indistinguishable from small interfering RNA (siRNA)-
directed transcript cleavage (12).
Polyomaviruses are small, nonenveloped viruses that contain
double-stranded circular DNA genomes of approximately 5 kb
and have been identified from various avian and placental
mammalian hosts (reviewed in references 14 and 21). We have
previously shown that several members of the Polyomaviridae,
including three human pathogens, encode miRNAs that lie
antisense to and with perfect complementarity to the early
transcripts (11, 33, 34, 40, 41). The early transcripts give rise to
the tumor antigen proteins (T antigens). These immunogenic
proteins perform various cell cycle regulatory and other func-
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tions to initiate and carry out viral genome replication. We
have identified miRNAs from human host viruses (JC virus
[JCV] [34], BK virus [BKV] [34], and Merkel cell carcinoma-
associated polyomavirus [MCV] [33]), Old World monkey
host viruses (SA12 [11] and simian virus 40 [SV40] [40]), and
the murine polyomavirus (muPyV) (41). In all cases, these
miRNAs lie antisense to the early transcripts, albeit their position
within the genome can vary by thousands of nucleotides. Analysis
of early transcripts and proteins, as well as chimeric reporters,
confirms that these miRNAs can direct siRNA-like cleavage of
the early T antigen transcripts. This can result in a reduction in
early protein levels in cell culture models of lytic infection (40,
41) and thus represents a form of viral autoregulation of gene
expression.
The fact that such evolutionarily divergent members of
the Polyomaviridae all encode autoregulatory miRNAs under-
scores the likely importance of this mode of gene expression
control. However, there are several observations that make the
importance of this regulation unclear. First, it is possible that
some polyomaviruses might not encode miRNAs. For exam-
ple, computational prediction using the Vmir software package
(11, 17, 39) fails to identify strong pre-miRNA candidates from
the WU virus (unpublished observations). Second, the degree
of negative regulation imparted on the early gene products is
only partial; abundant early protein levels are detectable at late
times of lytic infection with wild-type virus, and inhibition of
these miRNAs leads to only minor (a few fold or less) increases
in early protein levels (34, 40, 41). Third, lytic infection of
cultured cells with mutant SV40 or muPyV viruses (that are
defective for miRNA production) shows kinetics and virus
yields similar to those for infection with wild-type viruses (40,
41). Finally, acute in vivo infection of mice with the miRNA
mutant muPyV shows virus yields that are similar to those of
wild-type virus (41). In summary, the conserved autoregulatory
activity of the polyomavirus miRNAs implies importance; how-
ever, numerous observations (as discussed above) make the
degree and context of this importance unresolved.
To better understand polyomavirus miRNA function, we
sought to determine if an evolutionarily distant group of vi-
ruses that retain some features of the Polyomaviridae might
also encode miRNAs and employ similar modes of gene reg-
ulation. Bandicoot papillomatosis carcinomatosis virus types 1
and 2 (BPCV1 and BPCV2) comprise a fascinating group of
marsupial viruses that share distinct characteristics of both the
Polyomaviridae and Papillomaviridae (7, 46). The BPCV vi-
ruses encode T antigen early proteins and have a genomic
organization similar to that of polyomaviruses. Like all poly-
omaviruses, the BPCV genomes consist of an origin flanked
with promoters of opposing orientation that encode either the
early regulatory or late structural gene products. However, the
size of the BPCV genome and the genes encoding the late
proteins (L1 and L2) are most similar to those of the papillo-
maviruses. It has been theorized that the BPCVs are derived
from an ancient coinfection recombination event between a
polyomavirus and a papillomavirus (5).
Bandicoots comprise a genus of small to medium-sized
omnivorous marsupials. BPCV1 infects western barred bandi-
coots (Perameles bougainville), an endangered species whose
only remaining natural range is on the Bernier and Dorre
Islands in Western Australia. Infection with BPCV1 is associ-
ated with an often fatal papillomatosis and carcinomatosis
disease that is endemic among the western barred bandicoots
and has therefore hindered repopulation efforts (45). BPCV2
is a related virus that was isolated from a papillomatous lesion
from a southern brown bandicoot (Isoodon obesulus) (7).
BPCV1 and -2 display the hallmarks of a common evolutionary
ancestor, possessing similar genomic organizations and gene
products, and are 85% identical in nucleotide sequence.
Here, we show that both BPCV1 and -2 encode evolution-
arily conserved miRNAs that bind to and negatively regulate
transcripts containing the 3 UTR of the large T antigen
transcripts. This novel mechanism of T antigen regulation
lends strong support to the importance of miRNA-mediated
autoregulation in the polyomaviruses and polyomavirus-like
viruses.
MATERIALS AND METHODS
Ethics statement. The use of animals was noted as tissue samples, blood
samples, and cadavers collected at the Kanyana Wildlife rehabilitation center,
and therefore, a formal approval application was not necessary as determined by
the Murdoch University Department of Environment and Conservation Animal
Ethics Committee.
Cell culture and RNA isolation. Human embryonic kidney (HEK) 293 and
293T cells were obtained from American Type Culture Collection (Manassas,
VA) and maintained in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum (Cellgro, Virginia). Total RNA was harvested using an
in-house PIG-B solution (2 M guanidinium thiocyanate [EMD, New Jersey], 20
mM citrate buffer, pH 4.5, 5 mM EDTA [Fisher Scientific, New Hampshire],
0.25% Sarkosyl [Sigma Aldrich, Missouri], 48% saturated phenol, pH 4.5 [Am-
resco, Ohio], 2.1% isoamyl alcohol [Fisher Scientific], 0.5% -mercaptoethanol
[Sigma Aldrich], 0.1% 8-hydroxyquinoline [EMD], and 0.0025% Coomassie blue
[EMD]) as described previously (25a, 34, 44a).
Vector construction, transfection, and Northern blot analysis. All DNA vector
constructs were confirmed by sequence analysis through the Institute of Cellular
and Molecular Biology Sequencing Facility at the University of Texas at Austin.
A plasmid containing the entire BPCV1 genome (kindly provided by Lucy Wool-
ford, Murdoch University, Australia) was digested with the restriction enzyme
SalI (New England BioLabs, Massachusetts) and cloned into the XhoI site of the
pcDNA3.1puro expression vector. The resulting BPCV1 expression vectors were
named pBPCV1-Early and pBPCV1-Late. The plasmid pcDNA3.1-BPCV1-
NCR2, which contains the entire BPCV1 noncoding region 2 (NCR2) and partial
large T antigen and L1 open reading frame, was generated by cloning an ap-
proximately 1,500-bp PCR-amplified fragment of the BPCV1 genome into the
BglII/XhoI sites of the pcDNA3.1neo expression vector, removing the cytomeg-
alovirus (CMV) promoter in the process. The primers used were as follows:
BPCV1 NCR2 forward primer, ATCGATCGAAGATCTGGAGAAAGTTCTT
GTATCAGAGCAG, and BPCV1 NCR2 reverse primer, TAGCTAGCTCTCG
AGCCAAAGCTCATAAAGCAGAACTTG.
The plasmid pcDNA3.1-BPCV1-pro, in which the putative promoter in
NCR2 is replaced with a unique KpnI restriction site, was generated through a
three-way ligation between two PCR-amplified NCR2 fragments into the BglII/
XhoI sites of the pcDNA3.1neo expression vector. The primers used were as
follows: BPCV1 NCR2 KpnI reverse primer, ATCGATCGAGGTACCAGCTG
GGAACATCCCCTAAC, paired with the BPCV1 NCR2 forward primer described
above to generate the first fragment, and the BPCV1 NCR2 KpnI forward primer,
ATCGATCGAGGTACCTGCACACTGTGCACATGTATTG, paired with the
BPCV1 NCR2 reverse primer described above to generate the second fragment.
The plasmid pcDNA3.1-BPCV1-proNCR2, in which the entire NCR2 is de-
leted except for the BPCV1 pre-miRNA, was generated by digesting pcDNA3.1-
BPCV1-NCR2-pro using KpnI and BglII. The digested vectors were blunt
ended using Klenow fragment (New England BioLabs) and 10 mM deoxynucleo-
side triphosphates (dNTPs) (Invitrogen, California) at 37°C for 30 min. Follow-
ing Klenow fragment fill-in, the vectors were gel purified (Fermentas, Maryland)
and self-ligated using T4 DNA ligase (New England BioLabs). All constructs
were linearized by SalI restriction digestion prior to transfection into 293 cells.
The chimeric truncation construct containing an SV40 early promoter is the
nonlinearized form of pcDNA3.1-BPCV1-proNCR2.
The plasmids pcDNA3.1-BPCV1-miR-B1 and pcDNA3.1-BPCV2-miR-B1,
which express the BPCV1 miRNA and BPCV2 miRNA, respectively, were gen-
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erated by cloning an 400-bp PCR-amplified fragment of either the BPCV1
genome or the BPCV2 genome into the KpnI/XhoI sites of the pcDNA3.1neo
expression vector. The primers used were as follows: BPCV1-miR-B1 for-
ward primer, ATCGATCGAGGTACCGGATGTTCCCAGCTTATGTG,
and BPCV1-miR-B1 reverse primer, ATCGATCGACTCGAGGCAGAACTT
GAACTGTTAGACTC; BPCV2-miR-B1 forward primer, ATCGATCGAGGT
ACCGGCTGTTCCTACCGTATG, and BPCV2-miR-B1 reverse primer, TAG
CTAGCTCTCGAGTCAGAGCTTGAATTATTGGACTC. 293T cells were
plated in 6-well plates and transfected using the Lipofectamine 2000 reagent
(Invitrogen) according to the manufacturer’s instructions. 293T cells were also
transfected with empty pcDNA3.1neo vector as a negative control. Total RNA
was harvested at 48 h posttransfection. Ten micrograms of total RNA was
separated on a Tris-borate-EDTA-Urea-15% polyacrylamide gel. The gel was
transferred onto an Amersham Hybond N membrane (GE Healthcare,
Illinois) and probed for miRNA as previously described (17). The probe
sequences used were as follows: BPCV1 3p probe, GCGCACTCTCAAGCA
CAGTATT; BPCV1 5p probe, AAGTACTAAGCCTGAGAGTTCCCATGC
GATTCAAAAGT; BPCV1 loop probe, TATTATACTTTCGGTTTATAAAG
TACTA; BPCV1 downstream flank probe, GAGATTTTCAAATTATGTATC
TGCAATTAATGCTGAGA.
Computational prediction of viral pre-miRNAs, promoters, and polyadenyla-
tion recognition sites. A viral miRNA prediction algorithm, Vmir (24, 25), was
used to obtain candidate pre-miRNAs from the genomes of BPCV1 and BPCV2
(genome accession number NC_010107.1 and NC_010817, respectively). The
secondary structure of pre-miRNAs were predicted via the mfold RNA folding
prediction web server (48). The intrinsic promoters for both BPCV1 and BPCV2
were predicted via the Berkeley Drosophila Genome Project web server (7, 46).
The noncoding region 2 from BPCV1 and that from BPCV2 were analyzed in the
late orientation, with a default minimum promoter cutoff score of 0.80 (between
0 and 1.00). To predict the polyadenylation recognition and/or cleavage site of
the BPCV T antigen transcripts, two different algorithms were used (13, 42).
Small RNA library generation and computational analysis of sequencing
reads for SOLiD. 293T cells were plated in T75 flasks and transfected with either
pBPCV1-Early or pBPCV1-Late, using the Lipofectamine 2000 reagent as de-
scribed above. Total RNA was harvested at 48 h posttransfection as described
above. One hundred sixty micrograms of total RNA was gel fractionated to
isolate small RNAs. The gel fraction containing the10- to 70-nt size ranges was
excised. The excised gel fragment was cut into smaller pieces and soaked in 30 ml
of 1 M NaCl (Ambion, Texas) for 40 h at 4°C while under constant rotation
using a LabQuake shaker rotisserie (Thermo Fisher Scientific). The supernatants
were concentrated through centrifugation with the Vivaspin 15R concentrator
(Sartorius, Germany) at 3,000  g for 30 min at 4°C. The RNA was precipitated
by adding an equal volume of isopropanol and 1/10 total volume of 3 M sodium
acetate, pH 5.2 (Fisher Scientific). One microliter of glycogen (20 g/l; Invi-
trogen) was also added to the precipitation mixture to aid in the visualization of
the RNA pellet. RNA precipitation was done at 20°C overnight. The RNA
pellet was washed with ice-cold 75% ethanol and air-dried. The RNA was then
dissolved in water and converted into cDNA libraries for SOLiD sequencing as
previously described (25a). The 3 sequencing adapter sequence was trimmed
from the color space reads using custom Python scripts, and any sequences with
ambiguous calls or less than 18 nt in length after trimming were removed from
further analysis. The preprocessed reads were then mapped to the BPCV1
genome (NCBI accession number NC_010107.1) using the SHRiMP2 software
package (32). Uniqueness of reads of interest was further analyzed using the
BLAST algorithm and the “nr/nt” database (1). Secondary structure predictions
for regions with abundant reads were generated using the mfold server (48). 5p
start site counts and coverage relative to the total number of preprocessed reads
were calculated using custom Python scripts and visualized using the gnuplot
software package. Only reads with full-length perfect matches to the reference
genome were considered during the generation of coverage plots.
3 rapid amplification of cDNA ends (RACE) analysis to map the polyadenyl-
ation cleavage site of early transcripts. 293T cells were plated in 6-well plates
and transfected with pBPCV1-Early, using the Lipofectamine 2000 reagent as
described above. Total RNA was harvested at 48 h posttransfection as described
above. One microgram of the total RNA was reverse transcribed using Super-
script III (Invitrogen) reverse transcriptase according to the manufacturer’s
instructions. Two microliters of the reverse transcription product was used as
template for PCR using Phusion High-Fidelity DNA polymerase (Finnzymes,
Finland) according to the manufacturer’s instructions. The PCR product was
sequence analyzed through the Institute of Cellular and Molecular Biology
Sequencing Facility at the University of Texas at Austin. In addition, the PCR
products were TA cloned into pCR2.1-TOPO, and individual clones were se-
quenced. The primers used were as follows: reverse transcription primer, GAC
TCGAGTCGACATCGTTTTTTTTTTTTTTTTT; PCR forward primer, GAC
TCGAGTCGACATCG; PCR reverse primer, CCACCTACAGTAACTGTGA
GATG.
Luciferase assays. The BPCV1-miR-B1 and BPCV2-miR-B1 reporters were
constructed by cloning an 90-bp fragment corresponding to the entire large T
antigen 3 UTR noncoding region into the pcDNA3.1dsRluc vector, which ex-
pressed a destabilized version of Renilla luciferase (34), via the XhoI/XbaI sites.
The inserts were generated by oligonucleotide synthesis. For all oligonucleotides
used, see the list below. The negative control 2-nt seed-region-mutated reporters
contain engineered point mutations at the second and third nucleotides comple-
mentary to the 5 end of the BPCV 3p miRNA. The negative-control deletion
reporters contain internal deletions of the 3p miRNA binding site. The positive-
control perfect-match reporters contain a miRNA binding site that is perfectly
complementary to the BPCV 3p miRNA. 293 cells were plated in 12-well plates
and transfected using the FuGENE HD transfection reagent (Roche, Switzer-
land) according to the manufacturer’s instructions. Cells were transfected with
the reporter and the miRNA expression vector. 293 cells were also transfected
with the reporter along with either the MCV miRNA expression vector or empty
vector as negative controls. The pcDNA3.1Luc2CP vector was also cotransfected
to normalize for transfection efficiency. Cells were collected 48 h posttransfection
and analyzed with the Dual-Luciferase reporter assay system (Promega, WI)
according to the manufacturer’s instructions. The luciferase readings were col-
lected using a Luminoskan Ascent microplate luminometer (Thermo Fisher
Scientific). Results from the miRNA Renilla luciferase were normalized to the
firefly luciferase readings, and the ratios were plotted as a bar graph relative to
the empty vector control.
The primers used were as follows: BPCV1 WT forward primer, AAACTCGAG
CTGCTTGTTCTTTTCTGTGTGCACTCCCAAGCACAGTATTAAATAAA
CAGTGCT; BPCV1 WT reverse primer, TTTTCTAGAGGTAAAAAAACAT
TAGACACGGGTTTAGAGCAGCACTGTTTATTTAATACTGTG; BPCV1
Perfect forward primer (paired with BPCV1 WT reverse primer), AAACTCG
AGCTGCTTGTTCTTTTCTGTGCGCACTCTCAAGCACAGTATTAAATA
AACAGTGCT; BPCV1 Deletion forward primer, AAACTCGAGCTGCTTGT
TCTTTTCTGTAAATAAACAGTGCTGCTCTA.; BPCV1 Deletion reverse
primer, TTTTCTAGAGGTAAAAAAACATTAGACACGGGTTTAGAGCA
GCACTGTTTATTTACA; BPCV1 Point mutant forward primer, AAACTCG
AGCTGCTTGTTCTTTTCTGTGTGCACTCCCAAGCACAGTCATAAATA
AACAGTGCT; BPCV1 Point mutant reverse primer, TTTTCTAGAGGTAA
AAAAACATTAGACACGGGTTTAGAGCAGCACTGTTTATTTATGACT
GTG; BPCV2 WT forward primer, ATGATGCTCGAGGCTGTCTTTTGCTG
TCTGCGTGCACTCCCAAGCACAGTATTAATAAACAGTGCT; BPCV2
WT reverse primer, ATGATGTCTAGAGGTAAATAAACATTAGACACGG
GTTTTGAGCAGCACTGTTTATTAATACTGTGC; BPCV2 Perfect forward
primer (paired with BPCV2 WT reverse primer), ATGATGCTCGAGGCTGT
CTTTTGCTGTCTGCGCGCACTCTCAAGCACAGTATTAATAAACAGTG
CTG; BPCV2 Deletion forward primer, ATGATGCTCGAGGCTGTCTTTTG
CTGTCTGCAATAAACAGTGCTGCTCAA; BPCV2 Deletion reverse primer,
ATGATGTCTAGAGGTAAATAAACATTAGACACGGGTTTTGAGCAGC
ACTGTTTATTGCAG; BPCV2 Point mutant forward primer, ATGATGCTC
GAGGCTGTCTTTTGCTGTCTGCGTGCACTCCCAAGCACAGTCATAAT
AAACAGTGCTG; BPCV2 Point mutant reverse primer, ATGATGTCTAGA
GGTAAATAAACATTAGACACGGGTTTTGAGCAGCACTGTTTATTAT
GACTGTG.
Bandicoot lesion extraction, RNA isolation, and Northern blot analysis. An
adult western barred bandicoot (Perameles bougainville) severely affected by
multicentric papillomas and squamous cell carcinomas associated with BPCV1
infection was euthanized for humane reasons. Cutaneous papillomas and non-
lesional skin biopsy specimens were collected in sterile tubes and rapidly frozen
in liquid nitrogen. Skin samples were finely minced using sterile scalpel blades,
and then 20 mg of tissue was mixed with 350 l of RTL:-ME solution (1 ml
buffer RTL [Qiagen] with 10 l -mercaptoethanol) and homogenized using a
Heidolph DIAX 600 homogenizer (John Morris Scientific P/L, Bentley, Austra-
lia) for 5 min on the highest setting (24,000 min1). The lysate was centrifuged
at maximum speed in a microcentrifuge for 3 min and transferred to a fresh
microcentrifuge tube. Ethanol (100%) was added to the cleared lysate to bring
the final concentration up to 60% ethanol. Next, the samples were applied to an
RNeasy (Qiagen) mini-spin column to purify the total RNA according to the
manufacturer’s instructions, except that after the final wash step, the samples
were stored at approximately 4° C for several days while still on the column. The
final elution steps were conducted with one volume of nuclease-free water and
then repeated with one volume of nuclease-free Tris-EDTA (TE), pH 7.
Northern blot analysis was done as described for transfected samples (see
above). The blot was first probed with the 3p probe, stripped with boiling hot
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stripping buffer (0.1% sodium dodecyl sulfate [J.T. Baker, New Jersey] in double-
distilled water), and then probed with the control terminal loop probe. Due to
the small amount of nonlesional RNA negative-control sample that was avail-
able, a second Northern blot analysis was conducted using only 180 ng of non-
lesional RNA sample and lesional sample 1. The blot was first probed with the
3p probe, stripped as described above, and then probed with the loading control
probe (hsa-let-7a). The probe sequence for the hsa-let-7a probe was comple-
mentary to TGAGGTAGTAGGTTGTATAGTT.
RESULTS
Discovery of a BPCV1-encoded miRNA. To identify miRNAs
encoded by BPCV1, we subcloned the entire viral genome
downstream of a heterologous CMV promoter. Two different
vectors were created, each designed to drive expression of
transcripts from either the early or late orientation (pBPCV1-
Early and pBPCV1-Late) (Fig. 1A). Next, we transfected hu-
man embryonic kidney cells (293T) with either vector and then
isolated total RNA. The RNA was size fractionated to isolate
small RNAs (between10 to 70 nt in length), which were then
subjected to next-generation sequencing via the massively par-
allel SOLiD platform (2). Analysis of the pBPCV1-Early and
pBPCV1-Late sequencing results showed 39,390 and 82,208
reads, respectively, that mapped perfectly to the BPCV1
genome. Surprisingly, the vast majority of the reads from
both the pBPCV1-Early and pBPCV1-Late-transfected sam-
ples mapped to a single 22-nt RNA encoded in the late (pap-
illomavirus-like) orientation at nucleotides 4963 to 4984. This
region of the genome lies within the second noncoding region
(NCR2) that is located between the 3 ends of the T antigens
and L1/L2. (Fig. 1B). Although the distribution of reads from
both samples was surprisingly similar, we confirmed that the
sequencing reads were obtained from correct transfection
events, since we were able to isolate a few reads that spanned
the junctions of the plasmid vector backbone and the viral
genome (data not shown). The relative abundance and size of
this small RNA suggested it as a good candidate miRNA.
We then analyzed the genomic region surrounding this
abundant 22-nt RNA and predicted the secondary structure
(Fig. 1C). This analysis revealed a predicted hairpin structure
that possesses features common to many pre-miRNAs, includ-
ing a low G of41.20 kcal/mol, and a long stem portion (	30
nt) with few large asymmetrical bulges. The abundant 22-nt
RNA maps to the top portion of the 3 arm of the stem portion
of the predicted hairpin (Fig. 1C, indicated in bold). These
results suggest that the abundant 22-nt RNA could be a
miRNA derived from this hairpin pre-miRNA. Upon closer
inspection of the sequencing reads, we observed additional
evidence consistent with miRNA production. First, we ob-
served an enrichment in 35mer reads (the maximum read
length of our library) initiating at positions 4934 to 4936, with
the highest number of reads in both samples initiating at po-
sition 4934. These full-length reads are consistent with being
derived from the 5 end of the predicted pre-miRNA hairpin
structure. Second, we observed a small number of 21- to 23-nt
reads with 5 start sites coterminal with the full-length reads
that mapped to the 5 arm of the predicted hairpin stem,
consistent with it being a passenger strand derivative of a
putative pre-miRNA (typically, processing of a pre-miRNA
yields one abundant derivative, the “guide strand miRNA,”
and a less-abundant derivative from the other arm of the stem
called the “star strand” () or “passenger strand” miRNA).
Combined, these results strongly suggested that we had iden-
tified a pre-miRNA (and its derivatives) encoded by BPCV1.
To confirm the authenticity of this candidate miRNA, we
conducted Northern blot analysis using several different probes
(diagrammed in Fig. 1C). When probing with a radiolabeled
oligonucleotide that is perfectly complementary to the abun-
dant 22-nt RNA, we observed a prominent band migrating at
22 nt (Fig. 1F). In addition, we saw a fainter band migrating at
approximately 60 nt that is consistent with a pre-miRNA (Fig.
1F). Next, we probed for the other, less abundant strand and
observed a banding pattern completely consistent with it being
a passenger-strand RNA. Note that there are bands present at
22 nt and 60 nt but that the ratio of the smaller band to the
larger band is much lower than when probing for the guide-
strand derivative (Fig. 1D). We utilized two negative-control
probes, one designed to recognize the loop portion of the
pre-miRNA (which should not be processed into a stable,
smaller 22-nt RNA) and one designed to a flanking region
just outside the predicted hairpin region. As expected, the
“loop” probe detected a band consistent with the pre-miRNA
but did not detect any bands migrating at22 nt (Fig. 1E). The
negative-control “flank” probe did not detect any specific
bands (Fig. 1G). These results strongly suggest that the 22-
and 60-nt bands we detected are not due to nonspecific
degradation or siRNA generation, since in either of these
scenarios flanking genomic regions should also produce detect-
able small RNAs. Thus, we conclude we have identified a bona
FIG. 1. BPCV1 encodes a microRNA. (A) The BPCV1 genome was cloned into a heterologous expression vector in either the early or late
orientation. pBPCV1-Early and pBPCV1-Late were transfected, and 48 h posttransfection, small RNAs were size fractionated and subjected to
ABI SOLiD sequencing. Corresponding reads were mapped to the BPCV1 genome. The SalI restriction site used to subclone the viral genome
is indicated. (B) Coverage plot of deep sequencing reads. The frequencies of reads that mapped to the BPCV1 genome from the early and late
expression vectors are plotted (log2 scale) on the y axis. The x axis indicates BPCV1 genomic position. Each graph is divided into an early
orientation (top, rightward arrow) and a late orientation (bottom, leftward arrow), as indicated on the right side of the figure. The coverage plot
revealed abundant reads in both the early and late expression vector samples. The majority of the reads mapped a 22-nt RNA in the late
orientation, nucleotide position 4963 to 4984, located in the second noncoding region (NCR2). The gray angled arrowheads indicate the
high-scoring peaks. (C) Predicted secondary structure of the BPCV1 pre-miRNA and the associated probes designed to verify the deep sequencing
reads. The 3p miRNA is shown in bold. (D to G) Northern blot analysis confirms the expression of BPCV1-miR-B1. Probes were designed to
recognize the 5p miRNA (D), terminal loop (E), or 3p miRNA (F). An additional downstream flanking probe (flank, not diagrammed in panel
C) was used as a negative control (G). Both the 5p and 3p miRNAs were readily detectable, with the 3p miRNA the most abundant. As a loading
control, ethidium bromide-stained low-molecular-weight RNA is shown in the bottom panels. The bands corresponding to the pre-miRNA (gray
arrowhead) or the 5p and 3p miRNAs (black arrowhead) are indicated.
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fide BPCV1-encoded miRNA, and according to the conven-
tions of miRBase (15a), we name it “BPCV1-miR-B1.”
Evolutionary conservation of the BPCV1 miRNA. BPCV2 is
the only other known virus closely related to BPCV1, possess-
ing 85% nucleotide identity and a similar genomic organiza-
tion. An alignment of both genomes shows that the region
spanning the pre-miRNA shares 89.5% (153/171 nt) identity
(data not shown). These data imply a high likelihood that
BPCV2 would encode a miRNA homologous to BPCV1-miR-
B1. To test this notion, we first utilized a bioinformatic ap-
proach using the Vmir miRNA prediction software (17, 39,
40). This analysis showed that BPCV1-pre-miR-B1 scored as
the fifth-highest candidate in the late orientation and the 11th-
highest-scoring overall candidate (Fig. 2A, top panel; also data
not shown). Interestingly, this analysis showed that an analo-
gous region of the genome in BPCV2 predicted a candidate
pre-miRNA that scored even higher as the best candidate in
the late orientation and the second-best overall candidate (Fig.
FIG. 2. BPCV miRNAs are evolutionarily conserved. (A and B) Vmir predictions for BPCV1 and BPCV2 pre-miRNAs. The top panels show
the Vmir-predicted pre-miRNA candidates from BPCV1 and BPCV2. The y axis indicates the Vmir scores of the candidate pre-miRNAs. The x
axis indicates the genomic positions for BPCV1 and BPCV2, respectively. Candidate pre-miRNAs of the late orientation for both BPCV1 and
BPCV2 are indicated by triangles. Verified BPCV1-miR-B1 and BPCV2-miR-B1 are marked with a circle. The secondary structure predictions for
BPCV1 and BPCV2 pre-miRNAs are shown below each Vmir plot. The sequences of 3p miRNAs are indicated in bold. (C) Northern blot analysis
confirms that BPCV2 encodes a miRNA. The analysis was performed as described in the legend for Fig. 1.
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2B, top panel; also data not shown). Notably, this predicted
hairpin encompasses a 22-nt stretch that is 100% conserved
with the BPCV1 miRNA (Fig. 2A and B, bottom panels, indi-
cated in bold). To test if this high-scoring candidate miRNA is
actually made by transcripts derived from the BPCV2 genome,
we subcloned the entire BPCV2 NCR2 behind a chimeric
promoter, transfected cells, and harvested total RNA. North-
ern blot analysis of this RNA confirms that BPCV2 encodes a
miRNA homologous to that of BPCV1 (Fig. 2C). Accordingly,
we name this miRNA “BPCV2-miR-B1.”
Biogenesis of BPCV1-miR-B1. As described above, we ob-
tained numerous sequencing reads for BPCV1-miR-B1 irre-
spective of whether the RNA was harvested from cells trans-
fected with the early- or late-orientation expression vector.
Furthermore, Northern blot analysis readily identified the
miRNA from both constructs (Fig. 1C). Our ability to detect
the miRNA from the early-orientation construct implies that
an intrinsic robust promoter activity is present in the late (pap-
illomavirus) orientation of the BPCV genome that drives ex-
pression of BPCV1-miR-B1. Since both the BPCV miRNAs
are found within NCR2, and this region is not predicted to
encode any proteins (7, 46), we speculated that it may serve as
a cassette that contains a promoter to drive expression of the
primary transcripts that give rise to the BPCV miRNAs. To
test this hypothesis, we first subjected the NCR2 sequences
from both BPCV1 and BPCV2 to bioinformatic analysis (31)
to identify candidate promoter regions (Table 1). The highest-
ranked candidate promoter regions for both BPCV1 (nt 4769
to 4818) and BPCV2 (nt 4745 to 4794) were found to be in
similar genomic locations, approximately 60 nt upstream of
each respective BPCV pre-miRNA. Both of these candidate
promoters contain a putative TATA box (Table 1). A sequence
alignment between NCR2 of BPCV1 and that of BPCV2 re-
vealed that despite having only 73.9% (7) sequence identity in
this region, the pre-miRNA and putative promoter regions are
highly conserved (90%; 187/211 nt) (Fig. 3A), implying a
conserved function. To test for functional activity of these
putative promoters, a series of constructs was created (Fig.
3B). We first cloned the entire NCR2 of BPCV1, as well as
various truncations/internal deletions of this region. We indi-
vidually transfected each of these constructs and then con-
ducted Northern blot analysis for BPCV1-miR-B1 3p miRNA.
The construct containing the full-length NCR2 (named “1”
in Fig. 3B and C) expressed robust levels of the miRNA
(Fig. 3C). However, the truncation construct pcDNA3.1-
BPCV1-proNCR2, which has eliminated the predicted pro-
moter and all upstream sequences within NCR2 (nucleotides
3758 to 4808), showed a dramatic reduction in the expression
of the miRNA (Fig. 3C). To rule out the possibility that this
truncation mutation somehow compromised important fea-
tures of the pre-miRNA, we generated a chimeric construct
containing an SV40 early promoter upstream of this truncation
(named “3” in Fig. 3B and C). This chimeric construct was able
to rescue readily detectable levels of the miRNA. These data
argue that all essential cis processing elements for the pre-
miRNA lie within 60 nt of the base of the stem portion of
the predicted hairpin pre-miRNA. To determine if removal of
the predicted promoter region (nucleotides 4769 to 4808) was
sufficient to dramatically reduce transcription, an internal de-
letion mutant that deleted just the predicted promoter (pre-
serving the rest of the NCR) was created (pcDNA3.1-BPCV1-
pro, named “4” in Fig. 3B and C). This mutant construct
showed greatly reduced transcription, on par with that of
the large deletion mutation (pcDNA3.1-BPCV1-proNCR2,
TABLE 1. Predicted promoter sequences in BPCV1 NCR2 and BPCV2 NCR2a
Region
Position (nt)
Score Rank Predicted promoter sequence
Start End
BPCV1 NCR2 4769 4818 1.00 1 ATGTGGGCTTATAAAAGGGGCTGCAGAGGTCTGTA
GCTTGTGCACACTGT
4554 4603 1.00 1 GCATTCTCTATATAAAGCTGCAGCGGCCGTGCCGCT
TTTCGTTGCAGCCG
4546 4595 0.95 3 TGTTATATGCATTCTCTATATAAAGCTGCAGCGGCC
GTGCCGCTTTTCGT
4663 4712 0.93 4 AAAATAATTTTTAATAGCCTGGATATCTGCCATGAC
AGTTAAATCAGTAG
3852 3901 0.83 5 GGGAAATGTATAATTTTCAGGCCTACATCATTATGC
AGTTAGTCTGTGTG
BPCV2 NCR2 4745 4794 0.99 1 TATGTGGGTCTATAAAAGGGGCTGCAGAGGTCTGA
AAGCTGTGCACACTG
4710 4759 0.93 2 TATCCCCTGCACTAAAATATGGGCTGTTCCTACCGT
ATGTGGGTCTATAA
4929 4978 0.93 2 ACCGAAAGTATATAATACTGTGCTTGAGAGTGCGC
GGTAAATAAACATTA
4525 4574 0.90 4 TTTGTAAGTATATTACCGCCGTATCGGCTTATACCT
CTGCAGCCGCTCTG
4992 5041 0.84 5 AGCAGCACTGTTTATTAATACTGTGCTTGGGAGTGC
ACGCAGACAGCAAA
a Sequences from both BPCV1 NCR2 and BPCV2 NCR2 were subjected to promoter prediction via the Neural Network Promoter Prediction program (31).
The predictions were ranked according to their scores, from 0 to 1.00, with an arbitrary cutoff of 0.8. The start and end columns indicate the genomic location
of the predictions in BPCV1 and BPCV2. The nucleotides in bold are the predicted transcription start sites. The row shaded in gray represents the region containing
the promoter activity we identified in this study. The highest-ranked predictions for both BPCV1 and BPCV2 were located at similar relative genomic locations (nt 4969
to 4818 in BPCV1 and 4745 to 4794 in BPCV2), 60 nt upstream of the BPCV pre-miRNAs.
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FIG. 3. An evolutionarily conserved promoter in NCR2 drives the expression of the BPCV miRNAs. (A) Sequence alignment plot between
BPCV1 NCR2 and BPCV2 NCR2 revealed a highly conserved region upstream of BPCV1-miR-B1. The percentage of identity between BPCV1
and BPCV2 is calculated over a window of 20 nt and is plotted on the y axis. The x axis represents the genomic position of NCR2, with 1 being
the first nucleotide immediately downstream of the large T antigen stop codon. Black horizontal bars represent BPCV1-miR-B1-3p and -5p
miRNAs. The gray bar represents the position of the conserved promoter. (B) Deletion constructs used to map NCR2 promoter activity. The
construct, pcDNA3.1-BPCV1-NCR2, included flanking regions from both the L1 and large T antigen genes. Various internal deletion or truncation
constructs (as diagrammed) were assayed. The dotted lines represent the deleted region from NCR2, and the dashed lines represent vector
sequences. The column on the right indicates the expression of the miRNA relative to the FL construct, “” represent abundant miRNA
expression, “” represents intermediate miRNA expression, and “–” represents no detectable miRNA expression. (C) Northern blot analysis
from various NCR2 constructs identifies promoter activity at nucleotides 4769 to 4818. The 3p miRNA probe was used for the analysis. The loading
control, shown in the bottom panels, is ethidium bromide-stained low-molecular-weight RNA. The miRNA band is indicated by the black
arrowhead. (D) Northern blot analysis shows NCR2 promoter activity is conserved between BPCV1 and BPCV2. Analysis and labeling are as
described for panel C, above. The miRNA band is indicated by the black arrowhead.
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named “2” in Fig. 3B and C). Combined, these data support
the existence of a strong promoter in the BPCV1 genome that
lies upstream of the pre-miRNA, with essential elements at
nucleotide positions 4769 to 4818.
Since there is a high degree of conservation of the BPCV1
miRNA promoter region with BPCV2 (Fig. 3A), we examined
whether expression of the BPCV2 miRNA is driven by a sim-
ilar promoter. We subcloned the entire BPCV2 NCR2, con-
taining both the putative promoter region and pre-miRNA
regions, into a vector that does not contain a mammalian
promoter. This construct drove high expression of the BPCV2
miRNA to levels comparable to those for BPCV1 (Fig. 3D).
We therefore conclude that NCR2 of BPCV1 and BPCV2
each contain a robust transcription-inducing activity, making
the BPCV1 and -2 miRNAs some of the only viral miRNAs
with well-defined miRNA-specific promoters.
miRNAs encoded by BPCV1 and BPCV2 negatively regulate
transcripts containing the large T antigen 3 UTR via a man-
ner distinct from that of all known polyomaviruses. Because
all known Polyomaviridae miRNAs are encoded antisense to
the early transcripts, we wondered if this might also be the case
for the BPCV1 miRNA. Inspection of the genomic location of
BPCV1-miR-B1 shows that the miRNA lies 85 nt downstream
from the large T antigen stop codon (nucleotides 5070 to
5072). Two different algorithms predict a strong polyadenyla-
tion recognition site at nucleotides 5023 to 5028 in the early
orientation (13, 42; data not shown). If these predictions are
correct, it would mean that the early transcripts would likely
terminate before they reached the BPCV1 miRNA genomic
location encoded on the opposite strand. This would render
antisense miRNA-mediated cleavage of the early transcripts
impossible. We therefore performed 3 rapid amplification of
cDNA ends (3 RACE) analysis on RNA harvested from cells
transfected with pBPCV1-Early to map the 3 end of the
BPCV early transcripts. We sequenced PCR products as well
as individual clones from the RACE reaction. The results were
identical in both types of analyses—all sequencing reactions,
including the direct PCR products, as well as 9 out of 9 indi-
vidual clones mapped to the same site. These analyses mapped
a polyadenylation cleavage site between nucleotides 5008 and
5010 (since this region of the genome contains three thymi-
dines, it is unclear if the first three thymidines mapped are
derived from the genomic template or are added by the cellular
polyadenylation machinery) (Fig. 4A). This site is consistent
with the computationally predicted polydenylation site (13, 42)
and lies greater than 20 nt away from BPCV1-miR-B1. As
described in a later section, we were able to obtain RNA from
a natural BPCV1 infection of a western barred bandicoot, and
mapping of the 3 end of the early transcripts from this source
further confirms the polyadenylation cleavage site we mapped
in RNA harvested from transfected cells (sequencing of the
direct PCR products and 7 out of 7 individual clones mapped
a single location identical to the one mapped for the trans-
fected samples [Fig. 4A]). Combined, these data demonstrate
that unlike all known Polyomaviridae miRNAs, BPCV1-
miR-B1 is not encoded antisense to the early mRNAs but
rather lies in a separate downstream portion of the genome.
Therefore, BPCV1-miR-B1 does not possess perfect comple-
mentarity to the early mRNAs and is less likely to direct
siRNA-like, miRNA-mediated cleavage of these transcripts
(Fig. 4B).
During the course of analyzing the sequencing data, we
noted that performing a local BLAST search (1) of BPCV1-
miR-B1 to the BPCV1 genome produced two significant “hits”
at different locations within the genome. As expected, one hit
displayed a perfect 22-of-22-nt match and mapped to BPCV1-
miR-B1 itself. Unexpectedly, the other hit displayed a 20-of-
22-nt match that mapped to the 3 UTR of large T antigen
(Fig. 4A). Several reasons suggest this would be a likely target
site for regulation by BPCV1-miR-B1. First, the portion of
complementarity to the seed region (nucleotides 2 to 7, known
to play an especially important role in miRNA target recogni-
tion) (25) is a perfect match (Fig. 4C). Second, as discussed in
a later section, the BPCV1 T antigen 3 UTR complementary
region is 100% conserved (22 of 22 nt) with the related BPCV2
early 3 UTR, while the remaining portions of the 3 UTRs
share only 76.7% identity (33 of 43 nt). This implies a
conserved function in the putative miRNA target portion of
early transcript 3 UTRs. Third, miRNA target sites are
thought be more active when located close to the ends of the
3 UTR but greater than 15 nt from the stop codon (16), and
the putative BPCV1-miR-B1 target site matches these cri-
teria (close to both ends of the 3 UTR: only 20 nt from
the 3 terminus of the early transcripts and 19 nt down-
stream from the stop codon). Therefore, we set out to ex-
plore whether BPCV1-miR-B1 regulates transcripts con-
taining the early gene 3 UTR.
To test the hypothesis that BPCV1-miR-B1 regulates early
gene expression, we utilized Renilla luciferase reporter con-
structs containing the entire BPCV1 3 UTR. In addition, we
generated a negative-control 3 UTR containing a 2-nt point
mutation in the miRNA seed region, a second negative-control
3 UTR containing a deletion of the entire predicted 22-nt
binding region, or a positive-control 3 UTR containing an
engineered binding site that is perfectly complementary to the
BPCV1 miRNA (Fig. 5A). Cotransfection of a vector express-
ing BPCV1-miR-B1 with a reporter plasmid containing the
entire BPCV1 early 3 UTR results in a marked decrease in
luciferase expression (Fig. 5B). Notably, cotransfection of ei-
ther a control vector that does not express any miRNA or a
control vector expressing an irrelevant miRNA has little effect
on the luciferase activity of the plasmid containing the wild-
type BPCV early 3 UTR, thus implying specificity. Impor-
tantly, when we delete the entire putative miRNA target re-
gion or, more surgically, alter only two nucleotides within the
seed complementary region, we observe no negative regula-
tion. As expected, when we engineered a perfectly complemen-
tary reporter, we also observed BPCV1-miR-B1-specific neg-
ative regulation. Notably, the degree of regulation observed for
this positive-control reporter was similar to that of the natural
large T antigen 3 UTR reporter. These results strongly sug-
gest that BPCV1-miR-B1 can negatively regulate the BPCV1
early transcripts by binding to the 3 UTR. Thus, although 3
UTRs represent the most common locale of miRNA-mediated
repression in animals, this is the first demonstration of such
regulation for polyomavirus-like transcripts.
The BPCV1 large T antigen 3 UTR shares 84.6% identity
(55 of 65 nt) with BPCV2; however, the miRNA binding site is
100% conserved (22 of 22 nt) (Fig. 5C). Therefore, we hypoth-
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esized that BPCV2 would undergo miRNA-mediated regula-
tion of its early transcripts. To test this, we conducted experi-
ments identical to those described for Fig. 5A, except that we
utilized a reporter vector that contains the entire BPCV2 large
T antigen 3 UTR and a BPCV2 miRNA-expressing vector
(Fig. 5D). Strikingly, these results mirrored precisely the
trends we observed for BPCV1 (Fig. 5E) and suggest that this
novel form of miRNA-mediated regulation of the BPCV T
antigens is evolutionarily conserved.
BPCV1-miR-B1 is expressed in vivo. Infection with BPCV1
is associated with papillomas and carcinomas in western barred
bandicoots (46). PCR detection and in situ hybridization anal-
yses demonstrated that the virus is present in the majority of
papillomatous and carcinomatous lesions tested (6, 45, 46).
Because the western barred bandicoot is an endangered
species, obtaining tissue explants from infected animals is a
challenge. We were able to obtain both lesional and a small
amount of nonlesional tissue samples from a single infected
animal that had to be euthanized for humane reasons due to
complications arising from BPCV1-associated metastatic squa-
mous cell carcinoma. We harvested total RNA from two dif-
ferent lesional regions on the same animal, as well as nonle-
sional skin from a different portion of the animal. We were
pleased to observe a robust signal showing a specific band from
both lesional samples (Fig. 6A). This band comigrates with the
BPCV1-miR-B1 band that is detected in the positive-control
RNA derived from BPCV plasmid-transfected cells (Fig. 6A).
Probing any of four different negative-control samples, RNA
from nonlesional bandicoot skin (Fig. 6C), HEK 293 cells (Fig.
6A), HEK 293T cells (Fig. 6A), or BSC40 African green mon-
key cells (Fig. 6A), did not lead to detection of any specific
bands. As a control to rule out that the band we detected from
the lesional samples could be from random degradation of
total RNA, we stripped the blot in Fig. 6A and then reprobed
with the terminal loop probe (as described in the legend to Fig.
1C). If the band we detect is random degradation of a larger
viral transcript, then other probes for RNA sequences proxi-
mal to BPCV1-miR-B1 should also provide a signal at 22 nt.
Probing with the terminal loop probe (which recognizes an
RNA sequence just proximal to the miRNA) did not detect any
bands from the lesional samples (Fig. 6B). This result strongly
argues that neither random degradation fragments nor siRNAs
FIG. 4. The BPCV1 pre-miRNA is not complementary to the early transcripts. (A) 3 RACE analysis maps the polyadenylation cleavage site
of early transcripts. The polyadenylation cleavage site is indicated by a black triangle. “* and “#” indicate the number of individual clones that that
were mapped from the transfected or in vivo RNA samples, respectively. In both cases, all of the clones mapped the same polyadenylation cleavage
site. (B) Circular map of the BPCV1 genome shows the genomic location of the BPCV miRNA and the miRNA complementary site. (C) Diagram
showing the predicted base-pairing interaction between the BPCV1 miRNA and the miRNA binding site in the 3 UTR of the large T antigen
transcript. The canonical Watson-Crick base pairings are represented by the thick vertical lines; the wobble pairing is indicated with a thin vertical
line.
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can account for the miRNA signal we detect migrating at 22
nt, since both of these processes would be expected to generate
Northern blot-detectable bands throughout this region of the
genome (and not just from one arm of the pre-miRNA pre-
cursor hairpin). It is worth noting that the terminal loop probe
recognizes the pre-miRNA band in the positive-control RNA
sample but not in the lesional samples. Either of two explana-
tions likely accounts for this: (i) more-efficient processing of
FIG. 5. Evolutionarily conserved negative regulation of the 3 UTR of the early transcripts. (A) Diagram of a luciferase reporter construct
containing the entire 3 UTR of large T antigen, as well as control constructs. The vectors consist of a Renilla luciferase reporter upstream of a
single copy of the entire 3 UTR of BPCV1 large T antigen (WT), a negative-control 3 UTR containing a 2-nt point mutation in the miRNA seed
region (Pt), a negative-control 3 UTR containing a deletion of the predicted 22-nt binding region (Del), or a positive-control 3 UTR containing
an engineered site perfectly complementary to the BPCV1 miRNA (Perfect) at nucleotide positions 5043 and 5050. Numbers at either end indicate
the locations of the BPCV1 nucleotides that were cloned. (B) The BPCV1 miRNA negatively regulates the 3 UTR of large T antigen. The
reporters from panel A were cotransfected individually into 293 cells, and luciferase readings were normalized to those for firefly luciferase (FF.
luc) and plotted (y axis). The x axis indicates the different Renilla luciferase (R. luc) reporter constructs. The plasmids expressing either vector
alone, MCV miRNA, or BPCV1 miRNAs are indicated by the black, gray, and white bar graphs, respectively. P values were computed using
Student’s t test. “” indicates P 
 0.05, “” indicates P 
 0.01, and “” indicates P 
 0.001. (C) The miRNA binding site is 100% conserved
between the BPCV1 and BPCV2 3UTRs. The diagram depicts the level of conservation in miRNA and binding site between BPCV1 and BPCV2.
The region between the pre-miRNA and the large T antigen stop codon was divided into various regions, showing the percent conservation
between BPCV1 and BPCV2. The regions of 100% conservation are shaded in gray. The BPCV 3p miRNA is indicated by the black bar, and the
miRNA binding region is indicated by the gray bar. The BPCV1 nucleotide positions 4869–5072 and the BPCV2 nucleotide positions 4846 to 5051
were used in this conservation analysis. (D) The BPCV2 3 UTR is negatively regulated by the BPCV2 miRNA. Reporters similar to those
described above for panel A were engineered for the BPCV2 3 UTR. (E) Luciferase assays for the BPCV2 large T antigen 3 UTR reporters were
performed as described above for panel B.
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the pre-miRNA in vivo or (ii) a pre-miRNA nuclease activity
that is active in the preparation of the in vivo samples. Regard-
less, the fact that the loop probe recognizes the pre-miRNA
from the positive-control transfected sample rules out any
technical artifact that could account for its inability to detect
bands from the lesional tissue. Together, these data demon-
strate that the BPCV1 miRNA is expressed at high levels in
some contexts of in vivo infection.
DISCUSSION
The discovery of new virus-encoded miRNAs and under-
standing their functions represent an exciting developing sub-
field of virology. Here we describe miRNAs from a fascinating
group of recently described viruses, representing only the sixth
virus family/group shown to encode miRNAs. BPCV1 and
BPCV2 are remarkable because they represent natural hybrids
of two different virus families, the Polyomaviridae and the Pap-
illomaviridae. Like the polyomaviruses, the BPCVs express T
antigen proteins and have a genomic organization that consists
of an origin of replication flanked by promoters that drive the
regulatory T antigen transcripts in one direction around the
circular genome and drive the capsid transcripts in the other
direction (Fig. 7). However, unlike those of the polyoma-
viruses, the capsid proteins are clearly related to the papillo-
mavirus capsid proteins L1 and L2. Furthermore, the size of
the genome is7,300 bp, closer to that of the papillomaviruses
(7 to 8.5 kb) than the polyomaviruses (5.2 kb). In contrast
to the known polyomaviruses and most papillomaviruses, the
BPCVs also contain a long untranslated region (NCR2) of
FIG. 6. BPCV1-miR-B1 is expressed in vivo. (A) Northern blot
analysis scores positive for RNA harvested from either of 2 different
bandicoot lesions. Negative-control lanes are from human embryonic
kidney (HEK) 293 cells, HEK 293T cells, and BSC40 African green
monkey cells. RNA from cells transfected with BPCV1 miRNA-ex-
pressing plasmid is included as a positive control. The loading control,
shown in the bottom panels, is ethidium bromide-stained low-molec-
ular-weight RNA. The bands corresponding to the pre-miRNA (gray
arrowhead) or the 5p and 3p miRNAs (black arrowhead) are indi-
cated. (B) The signal detected from lesional tissue is not due to ran-
dom degradation. The blot from panel A was stripped and reprobed
with the terminal-loop-specific probe. The pre-miRNA band was de-
tected from the transfected positive-control sample, confirming the
activity of the probe. No signal from the lesional tissue was detected at
22 nt, ruling out that the band detected in panel B was due to random
degradation of transcripts spanning the pre-miRNA region of the
genome. The pre-miRNA detected by the terminal loop is indicated by
the gray arrowhead. (C) BPCV1-miR-B1 is expressed only in bandi-
coot lesions. Northern blot analysis of both nonlesional and lesional
RNA samples indicates that BPCV1-miR-B1 can be detected only in
lesional tissue. The loading control, shown in the bottom panel, is
Northern blot detection of the let-7a miRNA. The BPCV1-3p miRNA
is indicated by the black angled arrowhead.
FIG. 7. Model for miRNA-mediated viral gene regulation of Poly-
omaviridae and polyomavirus-like viruses. Both the polyomaviruses
and BPCV viruses encode miRNAs with the ability to negatively reg-
ulate the early T antigen transcripts. The mechanism of this regulation,
however, differs between the polyomaviruses and BPCV viruses.
BPCV viruses encode a miRNA that is located in a noncoding portion
of the genome and is not antisense nor fully complementary to the
early transcripts. All polyomaviral miRNAs that have so far been
reported are found antisense and complementary to the early tran-
scripts, albeit they are found in different regions of the genome.
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1.3 kb, which we have shown serves as both a promoter and
template to drive the primary miRNA-encoding transcript
(Fig. 1 and 3).
We have demonstrated that the BPCV miRNAs can direct
negative regulation of transcripts that contain the large T an-
tigen 3 UTR (Fig. 5A and B). This suggests that similar to
what has been observed in the polyomaviruses (33, 34, 40, 41),
herpesviruses (4, 15, 28, 44), and ascoviruses (19), BPCV
miRNAs play a prominent role in the regulation of viral gene
expression. This notion is supported by the observation that
the BPCV large T antigens have a relatively small 3 UTR at
60 nt (Fig. 4A); however, 20 of 22 are perfectly complemen-
tary to the miRNA. Since one of the mismatched target nu-
cleotides could bind as a GU wobble, this potentially leaves
only a single unpaired nucleotide between miRNA and mRNA
target site (Fig. 4C)—significantly fewer than almost all known
animal miRNA-target pairs.
Adding further weight to the model that BPCV1-miR-me-
diated viral gene regulation is relevant during infection is the
fact that 3 UTR regulation we observe is evolutionarily con-
served with BPCV2 (Fig. 5D and E). Using the Vmir miRNA
prediction software, we easily identified the pre-miRNA that
gives rise to BPCV2-miR-1 (Fig. 2B). Interestingly, the BPCV2
pre-miRNA scores as a higher-ranked candidate than BPCV1-
miR-1 (overall rank, 2 versus 11). We previously observed a
similar phenomenon for two different strains of MCV (33).
These observations have relevance to future attempts of using
bioinformatics approaches for identifying new viral miRNAs.
Rather than analyzing a single viral genome, future bioinfor-
matics efforts might be better served if a series of closely
related viruses, or even different isolates of the same virus,
were compared to identify common regions of predicted
pre-miRNAs. Finally, the fact that we show the BPCV1
miRNA is abundantly expressed during infection in vivo
(Fig. 6) argues that the regulation of the T antigen 3 UTR
we observe in cultured cells likely occurs in at least some in
vivo settings.
We have determined that the function of the second non-
coding region of the BPCVs includes encoding a promoter
and template for the primary transcript that contains the
pre-miRNA. We note that we cannot rule out that addi-
tional promoters and transcripts may be used to generate
this miRNA during some stages of infection. It is interesting to
point out that both NCR2 regions of BPCV1 and BPCV2
contain a predicted large T antigen binding site consensus
sequence of GAGGC (7, 29, 46). In addition, our observation
that this promoter is robustly active in cells derived from pla-
cental mammals suggests it is responsive to transcription fac-
tors that were present in the last common ancestor of placental
and marsupial mammals. Of note, possible host transcription
factor binding sites that are predicted in these NCR2 regions
include p53, E2F1, p300, and NF-B, (27; data not shown).
These observations suggest that regulation of the expression of
the BPCV miRNAs may be complex and affected by numerous
trans factors of both host and viral origin. Future experiments
are required to test this hypothesis.
We have previously shown that six different polyomaviruses
encode miRNAs that negatively regulate, or are predicted to
negatively regulate, T antigen transcripts. In all cases, despite
some sequence differences, these miRNAs are encoded on the
opposite strands and antisense to the T antigen transcripts (11,
33, 34, 40, 41). This conserved mode of regulation implies
importance; however, one could argue that since the degree of
regulation imparted by these is only partial (40, 41), the poly-
omaviral miRNA-mediated viral transcript regulation is a sec-
ondary consequence of the genomic location of these miRNAs.
However, the results we present here strongly imply that
some diverse viruses that have polyomaviral or polyomavi-
rus-like genomic organizations are under evolutionary pres-
sure to maintain miRNAs that regulate T antigen expression.
Because, unlike the polyomaviral miRNAs, the BPCV miR-
NAs are encoded in a different region of the genome (Fig. 4)
and possess an alternative mechanism of action (3 UTR reg-
ulation versus antisense miRNA-mediated cleavage of the cod-
ing sequence), we conclude that the miRNA-mediated regula-
tion of T antigen expression is selected for in diverse viruses.
We stress that in no way does this rule out the possibility
that important host targets exist for these miRNAs. Indeed,
as has been shown for several members of the Herpesviridae,
viral miRNAs will target virus-encoded or host-encoded
transcripts and sometimes a single miRNA can target both
(15, 36).
What is the purpose of polyomaviral and BPCV miRNA-
mediated regulation of T antigen transcripts? One possibility is
that, similar to the many Herpesviridae miRNAs that play a role
in latency, the polyomaviral and BPCV miRNAs may play a
role in maintaining persistent infection. In this scenario, these
miRNAs would prevent excessive or untimely expression of the
T antigens, thereby avoiding the triggering of inappropriate
lytic induction or clearance by the adaptive immune response.
In this regard, it is interesting to note that a putative T antigen
binding site exists in the NCR2 region of both BPCV1 and
BPCV2 (7, 29, 46). Thus, BPCV T antigen could play a role in
either a positive or negative feedback loop regulating expres-
sion of the miRNA. Currently, persistence is a poorly under-
stood facet of the polyomavirus life cycle. To further elucidate
the role of virus- encoded miRNAs in regulating persistent
and/or lytic infections, future studies will require the develop-
ment of appropriate in vivo models.
Finally, our results identify the first 2 viruses that encode
papillomavirus-like gene products that also encode a miRNA.
A previous study of human papillomavirus type 31 strongly
suggested that at least some papillomaviruses are not likely to
encode miRNAs (10). However, it is still formally possible that
other papillomaviruses may encode miRNAs. Our results sug-
gest that those papillomaviruses with multiple noncoding re-
gions, such as the Felis domesticus papillomavirus type 1, be-
longing to the genus Lambdapapillomavirus (30), would be
attractive candidates in a hunt for true papillomavirus-encoded
miRNAs.
In summary, we have shown that an interesting new group of
viruses encode miRNAs, which has important implications for
distantly related viruses, including some human pathogens. In
the future, exciting questions will be addressed, such as the role
of polyomavirus and polyomavirus-like miRNAs in possibly
targeting host transcripts and establishing or maintaining
persistent infection. What is clear at this point is that viral
miRNA-mediated regulation of viral transcripts is important
for divergent viruses, including herpesviruses, polyomaviruses,
and the BPCVs.
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